Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Agile Therapeutics Trading Up 2.4 %
Shares of NASDAQ:AGRX opened at $0.61 on Tuesday. The firm has a 50 day moving average of $0.92 and a 200 day moving average of $6.44. The firm has a market capitalization of $2.77 million, a price-to-earnings ratio of -0.02 and a beta of 1.23. Agile Therapeutics has a 12-month low of $0.49 and a 12-month high of $50.40.
Agile Therapeutics (NASDAQ:AGRX - Get Rating) last released its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($3.78) EPS for the quarter. The company had revenue of $1.76 million during the quarter. Agile Therapeutics had a negative return on equity of 599.24% and a negative net margin of 1,209.95%. Sell-side analysts predict that Agile Therapeutics will post -2.19 EPS for the current year.
Analysts Set New Price Targets
Several research analysts recently weighed in on AGRX shares. StockNews.com assumed coverage on shares of Agile Therapeutics in a report on Wednesday, August 3rd. They set a "sell" rating on the stock. Maxim Group raised shares of Agile Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, July 26th.